Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
Recap by typeshit. Full story at KTVH.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
A short social explainer from ABC7 Chicago on Lilly's experimental retatrutide and how it targets three hormones tied to appetite, with more at the station's link.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
A short teaser points to another reported side effect of GLP-1 drugs but doesn't say what it is.
Loading…